• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.

作者信息

Shava Emily, Izu Alane, Gaolathe Tendani, Walker Adam, Carty Lucy, Georgiou Panayiotis, Kuate Lesego, Kgathi Coulson, Sekoto Tumalano, Seonyatseng Ngozana, Mogashoa Tuelo, Maphorisa Comfort, Mohammed Terence, Ntalabgwe Tshenolo, Frank Tshepho T, Matlhaku Boitumelo, Diphoko Ame, Phindela Thandie, Kaunda Agripa, Kgari Poloko, Kanyakula Thomas, Palalani Gape, Phakedi Isabella, Taylor Sylvia, Mmalane Mompati, Moyo Sikhulile, Makhema Joseph

机构信息

Botswana Harvard AIDS Institute Partnership, Botswana.

South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Innovation/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases Unit, University of the Witwatersrand, Johannesburg, South Africa.

出版信息

J Infect. 2023 Jun;86(6):603-606. doi: 10.1016/j.jinf.2023.02.037. Epub 2023 Mar 1.

DOI:10.1016/j.jinf.2023.02.037
PMID:36863535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9974206/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26bc/9974206/d2dc9622d7fa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26bc/9974206/d2dc9622d7fa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26bc/9974206/d2dc9622d7fa/gr1_lrg.jpg

相似文献

1
Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.在博茨瓦纳接种ChAdOx1（AZD1222）新冠疫苗后新冠病毒病的安全性及发病率
J Infect. 2023 Jun;86(6):603-606. doi: 10.1016/j.jinf.2023.02.037. Epub 2023 Mar 1.
2
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.《6-17 岁儿童中 ChAdOx1 nCoV-19（AZD1222）疫苗的安全性和免疫原性：COV006 的初步报告，一项 2 期、单盲、随机、对照试验》
Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X.
3
AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal.用于新冠肺炎的阿斯利康新冠疫苗（Covishield）：尼泊尔的经验、挑战与解决方案
Travel Med Infect Dis. 2021 Mar-Apr;40:101989. doi: 10.1016/j.tmaid.2021.101989. Epub 2021 Feb 10.
4
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.鼻内接种腺病毒载体 COVID-19 疫苗的耐受性和免疫原性：一项开放性、部分随机、递增剂量的 I 期临床试验。
EBioMedicine. 2022 Nov;85:104298. doi: 10.1016/j.ebiom.2022.104298. Epub 2022 Oct 10.
5
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.异源初免-加强接种灭活 COVID-19 疫苗和 ChAdOx1 nCoV-19（AZD1222）疫苗的免疫原性和反应原性：一项准实验研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4.
6
A case of toxic epidermal necrolysis after ChAdOx1 nCov-19 (AZD1222) vaccination.1例ChAdOx1 nCov-19（AZD1222）疫苗接种后发生中毒性表皮坏死松解症的病例。
Australas J Dermatol. 2022 Feb;63(1):e93-e95. doi: 10.1111/ajd.13742. Epub 2021 Nov 9.
7
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.在朱拉隆功医院评估 ChAdox1 nCov-19（AZD1222）疫苗在实体瘤癌症患者中的免疫原性。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2104058. doi: 10.1080/21645515.2022.2104058. Epub 2022 Aug 17.
8
Aseptic meningitis following AZD1222 COVID-19 vaccination.接种 AZD1222 新冠疫苗后出现无菌性脑膜炎。
Am J Emerg Med. 2022 May;55:225.e5-225.e6. doi: 10.1016/j.ajem.2021.12.035. Epub 2021 Dec 18.
9
MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.接种 2019 年冠状病毒病（SARS-CoV-2）疫苗后发生 MOG 脑炎：病例报告及文献综述。
J Neurol. 2022 Oct;269(10):5198-5212. doi: 10.1007/s00415-022-11194-9. Epub 2022 Jun 23.
10
Extensive cutaneous lichen planus triggered by viral vector COVID-19 vaccination (ChAdOx1 nCoV-19).由病毒载体新冠疫苗（ChAdOx1 nCoV-19）引发的广泛性皮肤扁平苔藓
J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e263-e265. doi: 10.1111/jdv.17899. Epub 2022 Jan 5.

引用本文的文献

1
Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination: A single-arm open-label interventional study - final study results.AZD1222新冠疫苗的安全性以及在博茨瓦纳接种ChAdOx1（AZD1222）疫苗后SARS-CoV-2感染的低发生率：一项单臂开放标签干预性研究——最终研究结果
IJID Reg. 2023 Nov 10;10:35-43. doi: 10.1016/j.ijregi.2023.11.002. eCollection 2024 Mar.

本文引用的文献

1
Assessing the effectiveness of COVID-19 vaccines in Pakistan: A test-negative case-control study.评估新冠疫苗在巴基斯坦的有效性：一项检测阴性病例对照研究。
J Infect. 2023 May;86(5):e144-e147. doi: 10.1016/j.jinf.2023.01.016. Epub 2023 Jan 25.
2
Botswana's HIV/AIDS success.博茨瓦纳在防治艾滋病毒/艾滋病方面取得的成功。
Lancet. 2022 Aug 13;400(10351):480-481. doi: 10.1016/S0140-6736(22)01523-9.
3
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.南非 SARS-CoV-2 奥密克戎变异株的快速流行扩张。
Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7.
4
Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.先前感染过 COVID-19 与接种第一剂 BNT162b2/辉瑞疫苗后，但与接种第二剂疫苗后发生的不良事件（AEs）增加有关。
Vaccine. 2022 Jan 24;40(3):418-423. doi: 10.1016/j.vaccine.2021.11.090. Epub 2021 Dec 4.
5
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.ChAdOx1 nCoV-19（阿斯利康）疫苗对在巴西流行的 SARS-CoV-2 谱系的有效性。
Nat Commun. 2021 Oct 6;12(1):5861. doi: 10.1038/s41467-021-25982-w.
6
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.AZD1222（ChAdOx1 nCoV-19）新冠疫苗的 3 期安全性和疗效。
N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29.
7
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.在南非，针对有和没有 HIV 的人群的 ChAdOx1 nCoV-19（AZD1222）疫苗对 SARS-CoV-2 的安全性和免疫原性：一项随机、双盲、安慰剂对照、1B/2A 期临床试验的中期分析。
Lancet HIV. 2021 Sep;8(9):e568-e580. doi: 10.1016/S2352-3018(21)00157-0. Epub 2021 Aug 17.
8
ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.ChAdOx1新型冠状病毒疫苗对B.1.351变异株的有效性。回复。
N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.
9
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
10
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中，观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性（COV002）。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.